Coeptis Therapeutics Inc. (COEP): Utang agregat perusahaan

The company's debt position shows steady growth, confirming Coeptis Therapeutics' dependence on external financing due to early-stage testing. A lack of sales results in zero revenue and a capital burn. Meanwhile, management is betting on the synthesis of diagnostics and personalized cell therapy. The current value of 0.00 captures this metric, highlighting the risks of accumulating liabilities.

Developing innovative cell therapies to combat blood cancer requires significant capital, making the monitoring of debt load critical for assessing the financial stability of Coeptis Therapeutics (COEP). By analyzing the total debt level, an investor can track the dynamics of all credit obligations, allowing for a comparison of default risk against the potential for business expansion and the determination of the asset's overall investment attractiveness.